Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

Wilfried Rautenberg

Guenter Hoelzemann

Alfred Jonczyk

Helene Crassier

Teresa Mujica-Fernaud

Herwig Buchholz

Wolfgang Staehle

Christian Sirrenberg

Christophe Carola

Karl-August Ackermann

Hans-Peter Buchstaller

Gerd Bartoszyk

Hartmut Greiner

Christoph Van Amsterdam

Henning Boettcher

Jaume Adan

Elisabet Rosell-Vives

Dieter Dorsch

Christoph Seyfried

Kai Schiemann

Frank Stieber

Joachim Leibrock

Lars Thore Burgdorf

Gunter Holzemann

Günter Hölzemann

Francesc Mitjans

Juergen Harting

Arnulf Heubner

Rudlof Gottschlich

Gema Tarrason

Claudia Cases

Marta Soler Riera

Wolfgang Stähle

Lisa Matzen

Wolgang Stähle

Günter Hoelzemann

Novel compounds of the formula I in whichR, R, Rand Het are as defined herein, whichare inhibitors of tyrosine kinases and/or Raf kinases and can be employed for the treatment of tumors, for neuroprotection and for protection of the stress proteins of the skin.

Chromenone derivatives

The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases. (I) 

1,3-benzoxazolyl derivatives as kinase inhibitors

Compounds of the formula (I), in which R-R, R, R, Rand Rhave the meanings indicated in claim, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumors. 

N,N'-diphenylurea derivatives which are suitable as kinase inhibitors

The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. 

Heterocyclic substituted bisarylurea derivatives

Compounds of the formula (I), in which R, Rand X have the meanings indicated in Claim, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours. 

N,N'-diphenylurea derivatives suitable as kinase inhibitors

Disclosed are compounds of formula (I), which are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and which can be employed, inter alia, for the treatment of tumours.

Amine derivatives

Novel compounds of the formula I in which

2-oxadiazolechromone derivatives

Compounds of the formula (I), in which Rand Rhave the meanings indicated in Claim, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases, and can be employed, inter alia, for the treatment of tumours. 

Pyrazole derivatives

Compounds of the formula (I), in which R, R, R, R, Het, X and X' have the meanings indicated in claim, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours. 

4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours

Compounds of the formula (I), in which R&#x2014;R, R, R, Rand X have the meanings indicated in claim, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours. 

Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases

Compounds of the formula (I), in which R, X, R, R, Rand Rhave the meanings indicated in Claim (), are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours. 

Pyrazole derivatives having tyrosine kinase inhibitory activity

The invention relates to compounds of formula (I) wherein R, R, R, R, R, R, R, R, R, X and X' have the designations cited in patent claim. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors. 

Pyridopyrimidinones

Compounds of the formula (I), in which R, R, R, Rand X have the meanings indicated in claim, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours. 

Sulfonamides

Novel compounds of the formula I in which R, R, L, E, G, M, Q, U, R, m, p and q have the meanings indicated. Further, the compounds of formula I can be used as, for example, inhibitors of tyrosine kinases, for example TIE-2 , and can be employed, for example, for the treatment of tumours or other diseases. 

Growing community of inventors

Reinheim, Germany

Wilfried Rautenberg